頁籤選單縮合
題 名 | Atorvastatin降血脂療效探討=Evaluation of Atorvastatin Efficacy |
---|---|
作 者 | 林依儂; 吳淑娟; 詹尚易; | 書刊名 | 藥學雜誌 |
卷 期 | 32:1=126 2016.03[民105.03] |
頁 次 | 頁37-42 |
分類號 | 418.227 |
關鍵詞 | 降血脂治療; 療效比較; Atorvastatin; Antidyslipidemic therapy; Comparison of efficacy; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:Atorvastatin 早期的研究是低劑量治療,而現今加強型的治療劑量被預期將 有更大助益。本院併存有10 mg 及40 mg 兩種不同含量之藥品,藉由療效評估找出兩 者之治療優勢。 方法:自醫療照護系統擷取2013年9月1日至2014年10月31日使用 atorvastatin 10 mg 或40 mg 三個月以上之門診病人,分為 atorvastatin 10 mg 及40 mg 兩組,設定 efficacy outcome 及 safety outcome 進而分析比較兩組之差異。 結果:本研究發現 atorvastatin 10 mg 適合治療目標設定在 LDL < 130 mg/dL 之 病人,而 atorvastatin 40 mg 則適合目標為 LDL <100 mg/dL 或 LDL <70 mg/dL 的 病人。Efficacy outcome 中之 LDL >70 mg/dL 的事件發生率,atorvastatin 40 mg 比 atorvastatin 10 mg 少 (67.2% V.S. 87.1%,p < 0.05)。就安全性而言,兩者皆不會顯著 影響肝功能。 結論:血脂控制尚有進步的空間,在治療高危險群的病人時,應選用高劑量的 atorvastatin 為主。 |
英文摘要 | Objective: The therapy with low dose atorvastatin was typical in previous studies, but now high dose treatment is expected more beneficial for prevention of cardiovascular diseases. Our hospital had both atorvastatin 10 mg and 40 mg, and we tried to find their superiority by evaluation of the efficacy. Methods: We extracted the outpatients who had received atorvastatin 10 mg or 40 mg for three months form Sept. 1st 2013 to Oct 31st 2014 from healthcare information system. The eligible patients were assigned to two groups (10 mg V.S. 40 mg) and then compared the differences of efficacy outcome and safety outcome. Results: Our study found that atorvastatin 10 mg was appropriate for patients whose LDL goal less than 130 mg/dL and atorvastatin 40 mg was effective in lowering LDL to less than 100 mg/dL or 70 mg/dL. In efficacy outcome, the rate of LDL > 70 mg/dL occurring in atorvastatin 40 mg group was less than that in atorvastatin 10 mg group (67.2% V.S. 87.1%, p < 0.05). For safety concerns, two drugs didn't significantly affect liver function. Conclusion: We still need to put more efforts in antidyslipidemic therapy. Aggressive lipid control with high dose atorvastatin should be considered in patients with high risk factors. |
本系統中英文摘要資訊取自各篇刊載內容。